leisure time -WSS

leisure time

author：comprehensive 2025-10-02 17:56:38 - browse：9

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Cancer cells are shown to suck energy source from immune cells

focus

WSS

A letter from the executive editor: The 2023 STATUS List

STAT wants to know your pick for a great summer read or listen

Hubble vs. James Webb telescope images: See the difference

Peter Marks talks Operation Warp Speed for Rare Diseases

Undocumented workers face uncertainty as immigration law takes effect in Florida

European regulators consider appeal over Amylyx ALS drug

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Bright Health sells Medicare Advantage business to Molina

Drug cartel violence flares in western Mexico after vigilante leader's killing

Medicare details structure of new drug price negotiation program

Peter Marks talks Operation Warp Speed for Rare Diseases

Medical records are filled with copy

Female surgeons have lower rates of long

23andMe had bad news about my health. I wish a person had delivered it

Humana CEO Bruce Broussard to step down in 2024

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What the Wegovy shortage looks like for doctors — and for patients

knowledge

What affirmative action's end means to a medical student

What's changing in Medicare's open enrollment this year?

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

How Robert F. Kennedy Jr. distorted vaccine science

UpToDate has a racism problem: Dr. Stanley Goldfarb

Skip the lead apron during X

knowledge

focus

focus

entertainment